Canixa evolves with its innovative products, ultra-modern manufacturing facilities and highly skilled manpower, nurtured with utmost ethics. In the emerging world of Pharmaceutical market, Canixa has already emerged as a leading Dermatological player and aims to be among the paramount companies within the next decade. By forging trust, moving with agility and empowering innovation, we aspire to set global benchmarks in delivering value products to our customers. In addition, we are venturing into API manufacturing facilities and developing world-class Research and Development centres to ensure efficacy, affordability and qualitative medicinal products
To inspire humanity, with a motto of right to healthy life for millions around the globe, at Canixa our mission is to provide qualitative value added health care solutions beyond borders and establish ourselves as the leader in Dermatology by the year 2030.
Coined with the philosophy and ethical value of “Devoted to Support Life”, Canixa believes in making continuous effort to make the world disease free and brings smile to every face with a human touch.
In Canixa, people are the ultimate asset and epicentre of the organization. We reinvent people with shared knowledge, induce the power of optimism, freedom to explore, right to innovate and willingness to serve. Intertwined work ethics and high moral values, Canixans are able to scaling new ladders and prove their eminence. Canixans zest for ever sustained creative working culture helps the organization bloom with fulfilling rewards.
Key to Success
Inspired by our mission, guided by our philosophy and driven by our workforce’s unwavering devotion for health-care, we have come a long way. In an environment of clean corporate governance, every individual has a significant contribution to the overall development of the organization. We are thought-provoking, committed and supportive group of dynamic professionals from the pharmaceutical industry working towards a common goal: accessible and affordable health-care for all.